Seastar Medical Holding CORP (ICU) — SEC Filings
Latest SEC filings for Seastar Medical Holding CORP. Recent 10-K filing on Mar 25, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Seastar Medical Holding CORP on SEC EDGAR
Overview
Seastar Medical Holding CORP (ICU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: SeaStar Medical Holding Corp (ICU) reported significant progress in 2025, particularly with its Selective Cytopheretic Device (SCD) therapy. The company received FDA approval on February 21, 2024, for its pediatric SCD therapy, QUELIMMUNE, the only FDA-approved product for pediatric patients with ac
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant filing sentiment for Seastar Medical Holding CORP is mixed.
Filing Type Overview
Seastar Medical Holding CORP (ICU) has filed 1 10-K with the SEC between Mar 2026.
Recent Filings (1)
-
SeaStar Medical's SCD Gains Traction with FDA Nod, Strong Clinical Data
— 10-K · Mar 25, 2026 Risk: high
SeaStar Medical Holding Corp (ICU) reported significant progress in 2025, particularly with its Selective Cytopheretic Device (SCD) therapy. The company receive
Risk Profile
Risk Assessment: Of ICU's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
Key financial metrics from Seastar Medical Holding CORP's most recent 10-K filing (Mar 25, 2026):
- Revenue: N/A
- Net Income: N/A
- EPS: N/A
- Debt-to-Equity: N/A
- Cash Position: N/A
- Operating Margin: N/A
- Total Assets: N/A
- Total Debt: N/A
Industry Context
SeaStar Medical operates in the critical care medical device sector, focusing on inflammatory and organ failure conditions. The market is characterized by a need for innovative therapies that can address life-threatening conditions like AKI and sepsis, which often lead to significant morbidity and mortality. The company's SCD technology targets the underlying hyperinflammatory response, a common pathway in many critical illnesses, positioning it to potentially address a broad range of unmet needs.
Top Tags
Medical Devices (1) · Biotechnology (1) · FDA Approval (1) · Clinical Trials (1) · Acute Kidney Injury (1) · Sepsis (1) · Hyperinflammation (1)
Key Numbers
- Market Value of Non-Affiliate Voting Stock: $7.3M — As of June 30, 2025, indicating a small market capitalization.
- Active Commercial Hospital Customers: 10 — For QUELIMMUNE as of December 31, 2025, showing early commercial adoption.
- Reduction in Mortality: 50% — Validated by early QUELIMMUNE data compared to historical data.
- Reduced SAVE Registry Enrollment: 50 — FDA approved reduction from 300 to 50 patients for QUELIMMUNE.
- Patients Enrolled in NEUTRALIZE-AKI: 178 — Out of 339 total patients as of March 13, 2026, showing trial progress.
- Breakthrough Device Designations: 6 — Awarded by FDA for SCD therapy across multiple indications, accelerating regulatory pathways.
- FDA Approval Year: 2024 — For pediatric SCD therapy (QUELIMMUNE) on February 21, 2024.
- Anticipated PMA Submission Year: 2027 — For adult AKI SCD therapy, pending successful trial outcome.
- 60-Day Survival Rate: 76% — For pediatric patients in SAVE Surveillance Registry, demonstrating efficacy.
- Common Stock Outstanding: 3,993,719 — As of March 24, 2026, indicating share count.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Seastar Medical Holding CORP (ICU)?
Seastar Medical Holding CORP has 1 recent SEC filings from Mar 2026, including 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ICU filings?
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant sentiment is mixed.
Where can I find Seastar Medical Holding CORP SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Seastar Medical Holding CORP (ICU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Seastar Medical Holding CORP?
Key financial highlights from Seastar Medical Holding CORP's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ICU?
The investment thesis for ICU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Seastar Medical Holding CORP?
Executive information for Seastar Medical Holding CORP is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Seastar Medical Holding CORP stock?
Of ICU's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Seastar Medical Holding CORP?
Forward guidance and predictions for Seastar Medical Holding CORP are extracted from SEC filings as they are enriched.